UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia

Biological psychiatry (1969), 2015-12, Vol.78 (11), p.754-762

2015

Volltextzugriff (PDF)

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

The American journal of psychiatry, 2008-08, Vol.165 (8), p.1033-1039

2008

Volltextzugriff (PDF)

Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia

Neuropharmacology, 2012-03, Vol.62 (3), p.1473-1483

2012

Volltextzugriff (PDF)

Synthesis and Pharmacological Characterization of C4-Disubstituted Analogs of 1S,2S,5R,6S‑2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylate: Identification of a Potent, Selective Metabotropic Glutamate Receptor Agonist and Determination of Agonist-Bound Human mGlu2 and mGlu3 Amino Terminal Domain Structures

Journal of medicinal chemistry, 2015-02, Vol.58 (4), p.1776-1794

2015

Volltextzugriff (PDF)

Diverse Psychotomimetics Act through a Common Signaling Pathway

Science (American Association for the Advancement of Science), 2003-11, Vol.302 (5649), p.1412-1415

2003

Volltextzugriff (PDF)

Synthesis and Pharmacological Characterization of C4‑(Thiotriazolyl)-substituted-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylates. Identification of (1R,2S,4R,5R,6R)‑2-Amino-4-(1H‑1,2,4-triazol-3-ylsulfanyl)bicyclo[3.1.0]hexane-2,6-dicarboxylic Acid (LY2812223), a Highly Potent, Functionally Selective mGlu2 Receptor Agonist

Journal of medicinal chemistry, 2015-09, Vol.58 (18), p.7526-7548

2015

Volltextzugriff (PDF)

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders

Psychopharmacologia, 2007-07, Vol.193 (1), p.121-136

2007

Volltextzugriff (PDF)

Reduction of dendritic spines and elevation of GABAergic signaling in the brains of mice treated with an estrogen receptor β ligand

Proceedings of the National Academy of Sciences - PNAS, 2012-01, Vol.109 (5), p.1708-1712

2012

Volltextzugriff (PDF)

Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)

Psychopharmacology, 2005-04, Vol.179 (1), p.271-283

2005

Volltextzugriff (PDF)

Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system

Neurochemical research, 2003-04, Vol.28 (3-4), p.437-442

2003

Volltextzugriff (PDF)

Melanin-Concentrating Hormone-1 Receptor Modulates Neuroendocrine, Behavioral, and Corticolimbic Neurochemical Stress Responses in Mice

Neuropsychopharmacology (New York, N.Y.), 2006-06, Vol.31 (6), p.1135-1145

2006

Volltextzugriff (PDF)

Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039)

The Journal of pharmacology and experimental therapeutics, 2007-04, Vol.321 (1), p.308-317

2007

Volltextzugriff (PDF)

Muscarinic mechanisms in psychotic disorders

Handbook of experimental pharmacology, 2012 (213), p.233

2012

Volltextzugriff (PDF)

In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268)

The Journal of pharmacology and experimental therapeutics, 2009-12, Vol.331 (3), p.1126

2009

Volltextzugriff (PDF)

Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity

The European journal of neuroscience, 2003-04, Vol.17 (7), p.1403-1410

2003

Volltextzugriff (PDF)

Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats

The Journal of pharmacology and experimental therapeutics, 2005-03, Vol.312 (3), p.1055-1063

2005

Volltextzugriff (PDF)

Bassoon contributes to tau-seed propagation and neurotoxicity

Nature neuroscience, 2022-12, Vol.25 (12), p.1597-1607

2022

Volltextzugriff (PDF)

Cocaine is self-administered into the shell but not the core of the nucleus accumbens of Wistar rats

The Journal of pharmacology and experimental therapeutics, 2002-12, Vol.303 (3), p.1216-1226

2002

Volltextzugriff (PDF)

Regional heterogeneity for the intracranial self-administration of ethanol within the ventral tegmental area of female Wistar rats

Psychopharmacologia, 2000-04, Vol.149 (3), p.217-224

2000

Volltextzugriff (PDF)

Chronic pain impairs cognitive flexibility and engages novel learning strategies in rats

Pain (Amsterdam), 2018-07, Vol.159 (7), p.1403-1412

2018

Volltextzugriff (PDF)

Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties

Neuropsychopharmacology (New York, N.Y.), 2010-03, Vol.35 (4), p.855-869

2010

Volltextzugriff (PDF)

Hedonic and motivational responses to food reward are unchanged in rats with neuropathic pain

Pain (Amsterdam), 2016-12, Vol.157 (12), p.2731-2738

2016

Volltextzugriff (PDF)

Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344

The Journal of pharmacology and experimental therapeutics, 2006-02, Vol.316 (2), p.905-913

2006

Volltextzugriff (PDF)

Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor

Journal of medicinal chemistry, 2021-06, Vol.64 (12), p.8076-8100

2021

Volltextzugriff (PDF)

1 – 25 von 116

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(105)
Mit Volltextzugriff
(94)

Publikationsform

Sprache

Englisch
(116)

Erscheinungsjahr

n.n

Thema

Science & Technology
(64)
Life Sciences & Biomedicine
(58)
Animals
(56)
Rats
(37)
Pharmacology & Pharmacy
(35)
Male
(32)
Neurosciences
(29)
Neurosciences & Neurology
(28)
Biological And Medical Sciences
(26)
Mice
(23)
Rats, Sprague-Dawley
(23)
Dose-Response Relationship, Drug
(20)
Humans
(20)
Medical Sciences
(20)
Female
(19)
Psychiatry
(14)
Psychology. Psychoanalysis. Psychiatry
(13)
Mice, Knockout
(11)
Receptors, Metabotropic Glutamate - Agonists
(11)
Schizophrenia
(11)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Exploratory Analysis for a Targeted Patient Population Responsive to the Metabotropic Glutamate 2/3 Receptor Agonist Pomaglumetad Methionil in Schizophrenia

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

Group II metabotropic glutamate receptor agonists and positive allosteric modulators as novel treatments for schizophrenia

Diverse Psychotomimetics Act through a Common Signaling Pathway

In vivo pharmacological characterization of the structurally novel, potent, selective mGlu2/3 receptor agonist LY404039 in animal models of psychiatric disorders

Reduction of dendritic spines and elevation of GABAergic signaling in the brains of mice treated with an estrogen receptor β ligand

Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s)

LY2456302 is a novel, potent, orally-bioavailable small molecule kappa-selective antagonist with activity in animal models predictive of efficacy in mood and addictive disorders

Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system

Melanin-Concentrating Hormone-1 Receptor Modulates Neuroendocrine, Behavioral, and Corticolimbic Neurochemical Stress Responses in Mice

Pharmacological and pharmacokinetic properties of a structurally novel, potent, and selective metabotropic glutamate 2/3 receptor agonist: in vitro characterization of agonist (-)-(1R,4S,5S,6S)-4-amino-2-sulfonylbicyclo[3.1.0]-hexane-4,6-dicarboxylic acid (LY404039)

Muscarinic mechanisms in psychotic disorders

In vitro and in vivo evidence for a lack of interaction with dopamine D2 receptors by the metabotropic glutamate 2/3 receptor agonists 1S,2S,5R,6S-2-aminobicyclo[3.1.0]hexane-2,6-bicaroxylate monohydrate (LY354740) and (-)-2-oxa-4-aminobicyclo[3.1.0] Hexane-4,6-dicarboxylic acid (LY379268)

Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity

Pharmacologic interactions between the muscarinic cholinergic and dopaminergic systems in the modulation of prepulse inhibition in rats

Bassoon contributes to tau-seed propagation and neurotoxicity

Cocaine is self-administered into the shell but not the core of the nucleus accumbens of Wistar rats

Regional heterogeneity for the intracranial self-administration of ethanol within the ventral tegmental area of female Wistar rats

Chronic pain impairs cognitive flexibility and engages novel learning strategies in rats

Molecular Mechanisms of Action and In Vivo Validation of an M4 Muscarinic Acetylcholine Receptor Allosteric Modulator with Potential Antipsychotic Properties

Hedonic and motivational responses to food reward are unchanged in rats with neuropathic pain

Improved bioavailability of the mGlu2/3 receptor agonist LY354740 using a prodrug strategy: in vivo pharmacology of LY544344

Discovery and Early Clinical Development of LY3202626, a Low-Dose, CNS-Penetrant BACE Inhibitor

Suchergebnisse filtern